Expedited Processing Application No. 10/085,539 Amd. Dated: December 19, 2006

Reply to Final Office Action mailed October 20, 2006

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A site-specific drug delivery medical device

having a coating consisting essentially of at least one peroxisome proliferator-activated receptor

gamma (PPAR γ) agonist and at least one biocompatible polymer.

Claim 2 (previously presented): The site-specific drug delivery medical device

according to claim 1 wherein said PPARy agonist is rosiglitazone.

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (previously presented): The site-specific drug delivery medical device

according to any of claims 1 or 2 wherein said medical device is a stent.

Claim 6 (previously presented): The site-specific drug delivery medical device

according to claim 5 wherein said stent is a vascular stent or biliary stent.

Claim 7 (previously presented): The site-specific drug delivery medical device

according to claim 6 wherein said vascular stent is provided with a coating consisting essentially

of rosiglitazone and at least one biocompatible polymer.

Claim 8 (canceled)

Claim 9 (previously presented): The site-specific drug delivery medical device

according to claim 1 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone,

polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claim 10 (canceled)

Page 2 of 6

Expedited Processing Application No. 10/085,539 Amd. Dated: December 19, 2006 Reply to Final Office Action mailed October 20, 2006

Claim 11 (previously presented): A vascular stent consisting essentially of rosiglitazone; and

a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claims 12-26 (canceled)

Claim 27 (previously presented): The site-specific drug delivery medical device according to claim 7 wherein said biocompatible polymer is selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.